[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:alagille-syndrome":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":35,"states":36},"Alagille Syndrome",4,3,[8,15,21,27],{"nct_id":9,"title":10,"phases":11,"status":12,"updated_at":13,"content_modified":14},"NCT06850038","A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment",[],"RECRUITING","2026-08-26T02:16:06.684983Z","2026-05-13T02:55:06.584557Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT06193928","Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)",[],"2026-08-26T02:15:11.740957Z","2026-05-13T02:55:06.422866Z",{"nct_id":22,"title":23,"phases":24,"status":12,"updated_at":25,"content_modified":26},"NCT01793168","Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford",[],"2026-08-26T02:17:29.353236Z","2026-05-13T02:55:06.077983Z",{"nct_id":28,"title":29,"phases":30,"status":32,"updated_at":33,"content_modified":34},"NCT05035030","Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome",[31],"Phase 3","ACTIVE_NOT_RECRUITING","2026-08-03T02:46:50.671778Z","2026-05-05T02:43:29.521498Z",[],[37,40],{"state":38,"count":6,"slug":39},"California","california",{"state":41,"count":6,"slug":42},"Missouri","missouri"]